Literature DB >> 20567673

Experimental models of composite tissue allograft transplants.

Maria Siemionow1, Yalcin Kulahci.   

Abstract

Composite tissue allotransplantation has been recently introduced as a potential clinical treatment for complex reconstructive procedures including traumatic injuries, cancer ablative surgeries, or extensive tissue loss secondary to burns. Composite tissue allografts (CTAs) consist of heterogeneous tissues including skin, fat, muscle, nerves, lymph nodes, bone, cartilage, ligaments, and bone marrow with different antigenicities. Thus, composite tissue structure is considered to be more immunogenic than solid organ transplants. In this article, we present the experimental applications of CTA transplantation. To study the mechanisms of CTA acceptance and rejection, different experimental models, strategies, and different immunosuppressive protocols were used.

Entities:  

Keywords:  Composite tissue allotransplantation; experimental models; face; limb; vascularized bone

Year:  2007        PMID: 20567673      PMCID: PMC2884850          DOI: 10.1055/s-2007-991190

Source DB:  PubMed          Journal:  Semin Plast Surg        ISSN: 1535-2188            Impact factor:   2.314


  27 in total

1.  Functional tolerance following face transplantation in the rat.

Authors:  Maria Siemionow; Betul Gozel-Ulusal; Ali Engin Ulusal; Selahattin Ozmen; Dariusz Izycki; James E Zins
Journal:  Transplantation       Date:  2003-05-15       Impact factor: 4.939

Review 2.  Advances in composite tissue allograft transplantation as related to the hand and upper extremity.

Authors:  Maria Siemionow; Kagan Ozer
Journal:  J Hand Surg Am       Date:  2002-07       Impact factor: 2.230

3.  New surgical approach in facial transplantation extends survival of allograft recipients.

Authors:  Sakir Unal; Galip Agaoglu; James Zins; Maria Siemionow
Journal:  Ann Plast Surg       Date:  2005-09       Impact factor: 1.539

4.  Composite hemiface/calvaria transplantation model in rats.

Authors:  Ilker Yazici; Sakir Unal; Maria Siemionow
Journal:  Plast Reconstr Surg       Date:  2006-11       Impact factor: 4.730

5.  Combination of anti-ICAM-1 and anti-LFA-1 monoclonal antibody therapy prolongs allograft survival in rat hind-limb transplants.

Authors:  K Ozer; M Siemionow
Journal:  J Reconstr Microsurg       Date:  2001-10       Impact factor: 2.873

6.  Strategies to develop chimerism in vascularized skin allografts across MHC barrier.

Authors:  Yavuz Demir; Selahattin Ozmen; Aleksandra Klimczak; Abir Lal Mukherjee; Maria Z Siemionow
Journal:  Microsurgery       Date:  2005       Impact factor: 2.425

7.  Induction of tolerance in a rat model of laryngeal transplantation.

Authors:  Lee M Akst; Maria Siemionow; Olivia Dan; Dariusz Izycki; Marshall Strome
Journal:  Transplantation       Date:  2003-12-27       Impact factor: 4.939

8.  Extension of composite tissue allograft survival across major histocompatibility barrier under short course of anti-lymphocyte serum and cyclosporine a therapy.

Authors:  Kagan Ozer; Raffi Gurunluoglu; Maciej Zielinski; Dariusz Izycki; Murat Unsal; Maria Siemionow
Journal:  J Reconstr Microsurg       Date:  2003-05       Impact factor: 2.873

9.  Rat laryngeal transplant model: technical advancements and a redefined rejection grading system.

Authors:  Robert R Lorenz; Olivia Dan; Michael A Fritz; Marc Nelson; Marshall Strome
Journal:  Ann Otol Rhinol Laryngol       Date:  2002-12       Impact factor: 1.547

10.  Development of donor-specific chimerism and tolerance in composite tissue allografts under alphabeta-T-cell receptor monoclonal antibody and cyclosporine a treatment protocols.

Authors:  Kagan Ozer; Dariusz Izycki; Maciej Zielinski; Maria Siemionow
Journal:  Microsurgery       Date:  2004       Impact factor: 2.425

View more
  1 in total

1.  The Positive Impact of Donor Bone Marrow Cells Transplantation into Immunoprivileged Compartments on the Survival of Vascularized Skin Allografts.

Authors:  Arkadiusz Jundziłł; Aleksandra Klimczak; Erhan Sonmez; Grzegorz Brzezicki; Maria Siemionow
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-10-11       Impact factor: 4.291

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.